Menu
Board-certified neurosurgeon and scientist specializing in benign and malignant CNS tumors and tumor biology; Harvard, Harvard-MIT, BWH/Children’s Hospital, MGH; Director of Neuro-Oncology at Scripps Cancer Center; 20+ years tumor and vascular biology, The Scripps Research Institute.
20+ years of drug development experience; Previously, Head of CMC at Amplyx Pharmaceuticals, Head of CMC at Aristea Therapeutics. Drug development roles at Celgene, Pharmatek & Skypharma.
40+ years in executive management and drug development. 30-year career at AstraZeneca, leading teams that took six drugs through to approval and commercialization. Currently founder & CEO at Kateran Consulting, Inc. Prior roles: CEO and Founder of Aristea Therapeutics and CEO of Ardea Biosciences.
25+ years of hands-on experience in therapeutic biologics patent practice (Hybritech and beyond);
Previously IP partner at Morrison and Foerster; Stanford University School of Medicine, Adjunct Professor Department of Developmental Biology;
PhD in biochemistry and molecular biology.
20+ years of biotech executive management experience. CEO QUE Oncology, Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. Vice President of Preclinical and Clinical Research at SUGEN.
Vice President of Strategic Operations and San Diego Head at Biocom; 20+ years as an international business professional, Commercial Operations, Strategy; Prior roles: Chairman, President, CEO, CFO, COO.
10+ years in biotech, specializing in diagnostics, pathology, and genetics. Formerly, COO at HDNA, focusing on plant genetics, molecular breeding, advanced diagnostics and assay development.
Grace Furman, PhD
Regulatory Drug Safety & Toxicology
President & CEO Paracelsus, Inc.; Previously Divisional toxicologist at P&G, Agouron, and Pfizer.
Joyce James, PhD
Early Dev, and Clin. Pharmacology.
Founder & CEO, CORVID Consulting; Previously, founding member of Lyric, Pharmaceuticals, VP Odonate, Sr. Dir. at Cytokinetics and Ambit, playing a key role in the development of quizartinib.
Bridget O’ Keeffe, PhD
Peter Chen, MD, PhD
Board-certified Radiation Oncologist at Scripps Health: lung, CNS, soft tissue, & prostate cancer; Scientific Advisor.
Meredith Brown-Tuttle, RAC, FRAPS
Regulatory Affairs and QA
20+ years leading regulatory and quality programs; Senior Vice President Regulatory Affairs & Quality at Juvena Therapeutics.
Theresa Schaub, MBA<br>
Business Advisor
Commercial operations, product development, business integration, and drug discovery Executive leadership; Previously, VP Drug Discovery Millipore, VP Marketing Affymetrix/eBioscience, DiscoverX, Eurofins Discovery.
Copyright © 2024, Resolute Science, Inc. All Rights Reserved.
